Harvest Management’s Theravance Biopharma TBPH Stock Holding History

Harvest Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-6,194	Closed	-$228K	–	75
2017 Q1	$228K	Buy	+6,194	New	+$198K	0.18%	61
2016 Q4	–	Sell	-10,000	Closed	-$362K	–	82
2016 Q3	$362K	Sell	10,000 -3,000	-23%	-$83.5K	0.29%	53
2016 Q2	$295K	Buy	+13,000	New	+$281K	0.22%	58
2014 Q3	–	Sell	-7,999	Closed	-$255K	–	84
2014 Q2	$255K	Buy	+7,999	New	+$241K	0.26%	61

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Harvest Management's TBPH Position: Q2 2017 in Review

Harvest Management sold out of Theravance Biopharma (TBPH) in Q2 2017, closing a stake of 6,194 shares — an estimated $228K sold.

Harvest Management first reported a position in TBPH in Q2 2014 and held it in 4 quarters. The position peaked at $362K in Q3 2016. 94 funds tracked by Wall St. Rank hold TBPH as of Q2 2017.

Harvest Management reported no remaining Theravance Biopharma position as of Q2 2017 after selling out during the quarter.
Harvest Management sold 6,194 Theravance Biopharma shares in Q2 2017, an estimated $228K.
Harvest Management first reported a position in Theravance Biopharma in Q2 2014 and held it in 4 quarters.
Harvest Management's Theravance Biopharma position peaked at $362K in Q3 2016.
94 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2017.

Based on Harvest Management's 13F filing for Q2 2017, filed 11 Aug 2017.